Merck 2026 Financial Results are off to a powerful start as the science and technology giant reports a solid first quarter characterized by organic growth and a strategic upgrade to its full-year outlook. Despite facing significant foreign exchange headwinds, the Group generated net sales of €5.1 billion, representing an organic increase of 2.9%.
Strong Organic Growth Despite Currency Headwinds
The first quarter of the year has been a testament to Merck’s diversified portfolio. While reported sales saw a slight decline of 2.8% due to a 5.5% impact from foreign exchange, primarily the U.S. dollar and Asian market fluctuations, the underlying business remains robust.
EBITDA pre-reached €1.5 billion, growing 5.3% organically. This resilience has allowed the Executive Board to sharpen its strategic direction, focusing on integrated workflow solutions and high-growth technology sectors.
Our first-quarter performance underlines the strength of the company’s diversified portfolio,
Based on our performance… we upgrade our full-year 2026 financial guidance.
Kai Beckmann, Chairman of the Executive Board and Group CEO
Life Science and Electronics Drive the Momentum
A deep dive into the Merck 2026 Financial Results shows that the Life Science and Electronics business sectors were the primary engines of growth.
Life Science: Innovation at the Core
The Life Science sector saw organic sales grow by 8.3% to €2.3 billion. This was largely driven by Process Solutions, which surpassed the €1 billion threshold thanks to strong demand in downstream processing and single-use technologies.
- Discovery Solutions: Organic growth of 1.6% supported by academic and biotech spending.
- Advanced Solutions: Organic growth of 4.0%, helping customers in regulated manufacturing.
Electronics: AI and Semiconductor Trends
The Electronics sector benefited significantly from structural trends in Artificial Intelligence (AI) and high-performance computing. Semiconductor Solutions achieved organic growth of 7.5%, with Semiconductor Materials growing in the low-teens percentage range.
Healthcare Resilience and Portfolio Dynamics
While the Healthcare sector faced a challenging comparative base, it remained a vital pillar of the Merck 2026 Financial Results. Sales were bolstered by the Rare Diseases franchise, including the success of Ogsiveo® and Gomekli®. However, the sector saw an organic decline of 3.4% due to competition in the Oncology and Neurology franchises, specifically regarding Mavenclad® in the North American market.
Upgraded Full-Year 2026 Guidance
Following the strong start captured in the Merck 2026 Financial Results, the company has raised its target corridors for the remainder of the fiscal year:
| Metric | New 2026 Forecast | Organic Growth |
| Net Sales | €20.4 billion to €21.4 billion | 0% to +3% |
| EBITDA pre | €5.7 billion to €6.1 billion | -2% to +2% |
| EPS pre | €7.50 to €8.20 | N/A |
Strategic Direction and Long-Term Value
Merck is not just looking at the immediate numbers. The company is sharpening its operating model to focus on integrated solutions and the increased use of AI-platformed capabilities. This shift is designed to enhance scalability and speed, ensuring that the positive momentum from the Merck 2026 Financial Results translates into sustainable long-term growth
